Popular

Tirzepatide (GLP-1/GIP) – 30mg

Name: Tirzepatide (GLP-1/GIP) - 30mg - Orion Peptides
Price: 174.00 USD
Availability: InStock

30mg

Tirzepatide is an investigational synthetic dual-agonist peptide that activates the GIP and GLP-1 receptors.

$174.00

9 in stock

⁠Tirzepatide (GLP-1/GIP) – 30mg (10ML)

Tirzepatide (TR) is an investigational synthetic dual-agonist peptide that activates the GIP and GLP-1 receptors. It is a linear 39-amino-acid peptide that has been designed to contain a C20 fatty diacid chain via γ-glutamic acid spacer for prolonged circulating half-life and once-weekly pharmacokinetics. Tirzepatide has been investigated through in vitro lab research and observed challenges, including insulin secretion, blood glucose homeostasis, appetite regulation, body weight loss, triglyceride metabolism, and gastrointestinal motility. US-manufactured and supplied as high-purity lyophilized powder (≥99% via HPLC) in 30mg vials. Tirzepatide is for laboratory research use only in vitro and in vivo — it is not to be administered to humans, or used therapeutically or for any non-research purpose. For research use only. Strictly not for human consumption.

Tirzepatide Mechanism of Action in Research

Tirzepatide has a high affinity for and activates both GIP and GLP-1 receptors (family II G-protein-coupled receptors), stimulating G_s-protein signaling pathways and increasing intracellular cyclic AMP (cAMP) levels in target cells. Such dual agonism confers synergistic actions:

When activated, the GLP-1 receptor has anti-obesity effects through signalling in the central nervous system to suppress appetite, delay gastric emptying, and promote glucose-dependent insulin secretion while also repressing glucagon release when hyperglycaemic.
GIPR activation stimulates insulin secretion, enhances beta-cell functional reserve and regulates adipocyte lipid metabolism.

They describe a C20 fatty acid modification that allows for albumin binding, resulting in an extended plasma half-life of approximately 5 days and support for continued receptor activation in experimental models. These pathways are explored extensively in studies of metabolism regulation, energy balance, insulin sensitivity, and obesity-associated pathophysiology.

Tirzepatide Peptide Sequence

Tirzepatide is a 39-amino acid linear peptide, C-terminal amidated and lipidated: Tyr-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ (C20 diacid connected via γ-Glu linker at Lys²⁰)

Molecular formula:

C₂₂₅H₃₄₈N₄₈O₆₈ (approximate; lipidated)

Molecular weight:

≈4813 Da

CAS Number:

2023788-19-2 The lipid chain and requisite amino acid substitutions increase pharmacokinetic stabilities and receptor specificities.

Tirzepatide Research

1. Glucose Homeostasis and Insulin Secretion

Tirzepatide (0.1–10 nmol/kg s.c.) enhances glycemic control in preclinical models by increasing glucose-dependent insulin secretion and decreasing glucagon during hyperglycemia. In rodent studies, reductions in HbA1c-equivalent markers and fasting glucose can be stronger than those of GLP-1-only agonists, depending on the measures used.

2. Body Weight and Appetite Regulation

Dosage-dependent weight loss (up to 20–30% body weight change compared to placebo at higher doses, sustained over 12 weeks) in obese animal studies has been shown with tirzepatide. It inhibits feeding through GLP-1 and GIP receptor stimulation within the central nervous system, resulting in reduced meal size and frequency. Preferred fat mass loss with preservation of lean tissue is associated with greater energy expenditure and higher rates of lipid oxidation, according to the evidence.

3. Lipid Metabolism and Cardiovascular Parameters

In the high-fat diet model, Tirzepatide significantly decreases levels of circulating triglycerides, LDL cholesterol, and free fatty acids but improves the HDL profile. It attenuates liver steatosis and enhances insulin sensitivity in both liver and adipose tissue. There are positive effects in cardiovascular studies on blood pressure, endothelial function and atherosclerosis markers in preclinical atherosclerosis models.

4. Neuroprotective and Anti-Inflammatory Effects

Tirzepatide has been shown to have neuroprotective effects in neuronal cultures and animal models of neurodegeneration. It exerts anti-inflammatory effects by suppressing microglial activation and proinflammatory cytokine release. Research investigates its role in Alzheimer’s, Parkinson’s, and stroke models through GLP-1/GIP-driven anti-apoptotic and neurotrophic signaling. Tirzepatide is investigational — there is yet to be any large-scale, human approvable indication outside obesity/diabetes. Current investigations into the dual-agonist modes of action in metabolic homeostasis, energy balance, neuroprotection, and inflammation resolution are ongoing.

Tirzepatide Storage and Handling Instructions

Unopened vials are stored at room temperature at 2–8°C and protected from light and moisture. Do not freeze. Resuspend by aseptic addition of bacteriostatic water or sterile diluent. Refrigerate reconstituted solutions. Use within the stability window of the protocol (usually 4–6 weeks at 2–8°C). Avoid repeated freeze-thaw cycles. Every time, use sterile technique, gloves, and proper PPE.

Important Disclaimer

Tirzepatide is an experimental research peptide. For in vitro or in vivo laboratory studies only. Not approved for therapeutic, metabolic, weight management, or any other human medical use by the FDA, EMA, or any authority except as part of certain clinical trials. Information is based on data up until October 2023. Preclinical data do not correlate with human outcomes. No claims are made about safety, efficacy, or benefits in humans. Potential risks include immunogenicity or impurities. Only in qualified research facilities with institutional oversight. For laboratory use only — not for human or veterinary consumption.

Referenced Citations

Jastreboff AM, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.
Frías JP, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine.
Heise T, et al. (2023). Effects of tirzepatide on body weight and glycemic control in patients with type 2 diabetes. Diabetes Care.
Dahl D, et al. (2022). Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care.

Research Use Only

This product is intended for laboratory research use only. It is not intended for human or animal consumption, or for use in diagnostic or therapeutic procedures.

Chemical Properties

Molecular Formula	C225H348N48O68
Molecular Mass	4813 g/mol
Monoisotopic Mass	4810.5248574 Da
Polar Area	~1790 Å²
Complexity	11700
XLogP	-6.8
Heavy Atom Count	341
Hydrogen Bond Donor Count	58
Hydrogen Bond Acceptor Count	70
Rotatable Bond Count	163
CID	156588324
InChI	InChI=1S/C225H348N48O68/c1-23-126(10)183(214(327)242-131(15)190(303)…
InChIKey	AAPYRSPHYSKGIS-MCNPHUAVSA-N
IUPAC Name	(2S)-2-[[20-[[(5S)-6-[[(2S,3S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2-methylpropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-6-oxohexyl]amino]-20-oxoicosanoyl]amino]-5-[2-[2-[2-[2-[2-(carboxymethoxy)ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-5-oxopentanoic acid
SMILES	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N

Certificate of Analysis

Quality

Every batch of Tirzepatide (GLP-1/GIP) – 30mg is tested for purity and identity using industry-standard methods.

HPLC Analysis

High-Performance Liquid Chromatography confirms purity ≥98%. Each batch is analyzed to ensure consistent quality.

Mass Spectrometry (MS)

Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol.

Third-Party Testing

All products undergo independent third-party laboratory testing for quality assurance.

Request COA

Certificate of Analysis documents are available for all products. Contact us with your order number to request batch-specific documentation.

COA Lab Tests

Each product batch is tested by independent laboratories to verify purity, identity, and quality. The Certificate of Analysis (COA) provides transparent lab results, ensuring the product meets strict research-grade standards.

Storage & Handling

Refrige⁠ration Guidelines

Store unop‍ened pens or vials at 36°F to 46°F.
Do not freeze the medicatio‍n under any⁠ ci⁠rcumstances
Keep in the origina‍l‍ carton to protect from lig‌ht
Discard i‍mmediately if medication free⁠zes
Mark the date when the pen leaves refrigeration to track the 21-day room temperature window

R‍oom Temperature Storage

Refr‍i‍ge‌ration pref‍erred until use
Can b‍e‌ stor‍ed at room tempe⁠rature for 21 days⁠
⁠Do n⁠ot exceed tempe‍ratures above‌ 86°F
Discard any leftover m‌edicat‌i⁠on after recommended ti‌me period

Travel and Transpo⁠rt

Use insulated bag or sm⁠all cool‌er for travel
Keep medication cold with ice packs
Avoid direct contact betwee⁠n medication and ice
Maint‍ain proper temperature throughout t‌h‍e journey

R‍oom Temperature Storage

Refr‍i‍ge‌ration pref‍erred until use
Can b‍e‌ stor‍ed at room tempe⁠rature for 21 days⁠
⁠Do n⁠ot exceed tempe‍ratures above‌ 86°F
Discard any leftover m‌edicat‌i⁠on after recommended ti‌me period

Tirzepatide (GLP-1/GIP) – 30mg

Bulk Pricing – Save More

⁠Tirzepatide (GLP-1/GIP) – 30mg (10ML)

Tirzepatide Mechanism of Action in Research

Tirzepatide Peptide Sequence

Molecular formula:

Molecular weight:

CAS Number:

Tirzepatide Research

1. Glucose Homeostasis and Insulin Secretion

2. Body Weight and Appetite Regulation

3. Lipid Metabolism and Cardiovascular Parameters

4. Neuroprotective and Anti-Inflammatory Effects

Tirzepatide Storage and Handling Instructions

Important Disclaimer

Referenced Citations

Research Use Only

Chemical Properties

Certificate of Analysis

Quality

HPLC Analysis

Mass Spectrometry (MS)

Third-Party Testing

Request COA

COA Lab Tests

Storage & Handling

Refrige⁠ration Guidelines

R‍oom Temperature Storage

Travel and Transpo⁠rt

R‍oom Temperature Storage

Related Products

Purity

Storage

5 Amino 1MQ – 10mg

AOD-9604 – 10mg

AOD-9604 – 2mg

AOD-9604 – 5mg

AOD-9604 (10mg) + Tesamorelin (10mg) Research Kit

Bacteriostatic Water 10ml

BPC 157 (10mg) + TB 500 (10mg) + GHK-Cu (50mg) + KPV (10mg) Blend

BPC 157 (10mg) + TB 500 (10mg) Blend

BPC 157 (5mg) +TB 500 (5mg) Blend

BPC-157 – 10mg

BPC-157 – 5mg

BPC-157 (10mg) + TB-500 (10mg) Bundle

BPC-157 (5mg) + TB-500 (5mg) Starter Kit + BAC Water (10ml) | Peptide Research Bundle

CJC-1295 (No DAC) – 2mg

CJC-1295 (No DAC) – 5mg

CJC-1295 (No DAC) (5mg) + Ipamorelin (5mg) Research Bundle

CJC-1295 No DAC (10mg) + Ipamorelin (10mg) Blend

CJC-1295 NO DAC (5mg) + Ipamorelin (5mg) Blend

DSIP – 5mg

Epithalon (20mg) + SS-31 (Elamipretide) (5mg) Longevity Research Kit

Epithalon (Epitalon) – 10mg

Epithalon (Epitalon) – 20mg

GHK-Cu – 100mg

GHK-Cu – 10mg

GHK-Cu – 50mg

GHK-Cu (50mg) + Epithalon (10mg) Bundle

Glutathione (10ML) – 500mg

Glutathione (10ML) – 600mg

IGF-1 LR3 – 1mg

Ipamorelin – 10mg

Ipamorelin – 2mg

Ipamorelin – 5mg

Kisspeptin-10 – 5mg

L-Carnitine – 600mg

Melanotan I (MT1) – 5mg

Melanotan II (MT2) – 10mg

MOTS-c – 10mg

MOTS-c (10mg) + NAD+ (500mg) Bundle

NAD+ – 100mg

NAD+ – 500mg

Oxytocin – 2mg

PT-141 – 10mg